Health Care Equipment

Nuwellis

Nuwellis released FY2026 Q1 earnings on May 12 Pre-Market (EST), actual revenue USD 2.403 M (forecast USD 2.094 M), actual EPS USD -2.09 (forecast USD -1)

Nuwellis to Release FY2026 Q1 Earnings on May 12 Pre-Market EST, Forecast Revenue USD 2.094 M, EPS USD -1

Nuwellis released FY2025 Q4 earnings on March 11 Pre-Market (EST), actual revenue USD 2.424 M (forecast USD 2.31 M), actual EPS USD -1.4998 (forecast USD -1.56)

Nuwellis released FY2025 Annual Earnings on March 11 Pre-Market (EST), Actual Revenue: USD 8.27 M (Forecast: USD 8.156 M), Actual EPS: USD -25.3816 (Forecast: USD -25.72)

Nuwellis to Release FY2025 Q4 Earnings on March 10 After-Market (EST), Forecast Revenue USD 2.31 M, EPS USD -1.56

Maxim Group Analyst Maintains Hold Rating on Nuwellis

Nuwellis released FY2025 9 Months Earnings on November 12 Pre-Market EST with actual revenue of USD 5.846 M and EPS of USD -89.3506

Nuwellis released FY2025 Q3 earnings on November 12 Pre-Market (EST), actual revenue USD 2.217 M (forecast USD 2.5 M), actual EPS USD 0.5607 (forecast USD -17.22)

Nuwellis to Release FY2025 Q3 Earnings on November 12, Pre-Market EST; Forecast Revenue USD 2.5 M, EPS USD -17.22

Nuwellis released FY2025 Q2 earnings during market hours on August 14 (EST), actual revenue USD 1.725 M (forecast USD 2.2 M), actual EPS USD -60.9796 (forecast USD -18.9)

Nuwellis released FY2025 Semi-Annual earnings on August 14 During-Market EST, actual revenue USD 3.629 M, actual EPS USD -100.4251

Nuwellis Plans to Cease International Operations

Nuwellis to release FY2025 Q2 earnings report on August 12 During-Market EST, forecast revenue USD 2.2 M, EPS USD -18.9

Nuwellis Inc Terminates Reverse HF Clinical Trial

Nuwellis Gains Fluid Management Patent, Stock Soars 61%

Nuwellis Completes $5 Million Underwritten Public Offering

Nuwellis, Inc. Announces Public Offering of Shares and Warrants

Nuwellis released FY2025 Q1 earnings during market hours on May 13 (EST), actual revenue USD 1.904 M (forecast USD 2.5 M), actual EPS USD -28.9316 (forecast USD -18.9)

Nuwellis reports Q1 2025 financial results

Nuwellis signs contract with KDI to strengthen production

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

NUWE

Nuwellis (NASDAQ:NUWE) reported a 26% year-over-year revenue increase for Q1 2026, driven by stronger console and circuit sales. Gross margin improved to 70.1% due to better pricing and product mix. The company completed a $5 million private placement and appointed Carissa Schultz as CFO. Nuwellis expanded its cardiorenal platform by acquiring Rendiatek, enhancing kidney function monitoring. Pediatric care now accounts for 50% of U.S. revenue, with expansion into 47 centers nationwide. The quarter marked a shift from strategic reset to execution, strengthening leadership and capital foundation.

benzinga_article

Nuwellis Q1 2026 Earnings Call Transcript

NUWE (Nuwellis, Inc.) is set to announce its Q1'26 results on May 12, after the market closes. The earnings are expected to be disclosed at 8:15 AM ET (12:15 PM UTC).For Q1'26, revenue estimate is 2.09 million USD with EPS (earnings per share) anticipated at (1.00) USD. Learn more details at .Revenue & EPS values are provided in USDQ1'25Q2'25Q3'25Q4'25Q1'26Revenue Reported1.90 M1.73 M2.22 M2.42 M—Revenue Estimate2.50 M2.20 M2.50 M2.31 M2.09 MRevenue Surprise-23.84%-21.59%-11.32%+4.94%EPS Reported(28.98)(60.99) 0.56(1.50) EPS Estimate(18.90)(18.90)(17.22)(1.56)(1.00) EPS Surprise-53.33%-222.70%+103.25%+3.85%DisclaimerSelect reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.

TradingView

Factset Research

NUWE Q1'26 Earnings: EPS estimate is (1.00) USD

Nuwellis, Inc. has settled a lawsuit with E.F. Hutton, agreeing to pay $204,000 without admitting liability. The lawsuit, filed in February 2026, alleged breach of an engagement letter for securities offerings. The settlement includes a mutual release of claims and dismissal of the lawsuit. Currently, Nuwellis stock (NUWE) holds a Hold rating with a price target of $1.31, but faces challenges due to weak financial fundamentals and ongoing losses. The company's market cap is $2.93M, and it operates in the medical technology sector, relying on capital markets for growth.

Tip Ranks

Nuwellis Settles Lawsuit With E.F. Hutton, Resolving Dispute

Nuwellis, Inc. has announced a software update for its Aquadex SmartFlow® ultrafiltration platform, aimed at enhancing usability and clinical workflow. The update features a more precise ultrafiltration adjustment capability, particularly beneficial for pediatric care. Key improvements include a refined blood flow algorithm, enhanced resistance graph, and expanded data logging. The update is available at no cost to existing customers and reflects Nuwellis' commitment to continuous improvement based on customer feedback. CEO John Erb emphasized the importance of this update for fluid management in pediatric patients, the company's fastest-growing customer segment.

fidelity

Nuwellis Announces Aquadex Software Update

Nuwellis Board Directors Resign Amid Governance Dispute

Nuwellis Board Directors Resign Amid Governance Dispute

Nuwellis(NUWE.US)

Nuwellis Q1 2026 Earnings Call Transcript

NUWE Q1'26 Earnings: EPS estimate is (1.00) USD

Nuwellis Settles Lawsuit With E.F. Hutton, Resolving Dispute

Nuwellis Announces Aquadex Software Update

Nuwellis Board Directors Resign Amid Governance Dispute